Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   BioPharma   /   Genmab, de Deense parel

BioPharma« Terug naar discussie overzicht

Genmab, de Deense parel

Volgen
145 Posts
Pagina: «« 1 2 3 4 5 6 ... 8 »» | Laatste | Omlaag ↓
  2. [verwijderd] 10 februari 2007 08:46
    CAPITAL INCREASE IN GENMAB AS A RESULT OF EXECUTION OF PRIVATE PLACEMENT TO GLAXOSMITHKLINE

    Copenhagen, Denmark; February 7, 2007 - Genmab A/S (CSE: GEN) hereby announces the direct placement of 4,471,202 ordinary Genmab A/S (the "Company" or "Genmab") shares of DKK 1 nominal value each at a subscription price of DKK 454.65 per share in a private placement (the "Placement") to Glaxo Group Limited "GSK". This Placement which is made in connection with the worldwide agreement to co-develop and commercialize HuMax-CD20 was originally announced on December 19, 2006.

    Genmab's current share capital amounts to DKK 39,648,355 and will after completion of the capital increase be DKK 44,119,557.

    It is expected that the new shares will be admitted for listing on the Copenhagen Stock Exchange on February 9, 2007 after registration with the Danish Commerce and Companies Agency.

    The statutory private placement memorandum prepared in Danish in connection with the Placement has been approved by the Danish Financial Supervisory Authority and published in accordance with applicable rules.
    www.genmab.com/upload/filing_of_prosp...
  3. [verwijderd] 13 februari 2007 18:12
    Preliminary Annual Report
    2006
    (February 13, 2007)

    Letter from the Chief Executive
    Officer
    Dear Shareholder,
    2006 has been the most exciting year in Genmab’s
    history. Our key achievements in 2006 included entering
    a global co-development and commercialization
    agreement with GlaxoSmithKline (GSK) for HuMax-
    CD20™ (ofatumumab), initiating three new pivotal
    studies, reporting positive results in the HuMax-CD20
    and HuMax-CD4® (zanolimumab) clinical development
    programs, developing the UniBody™ technology
    and completing a private placement of new shares. As
    a result of this careful execution of our business
    strategy, we saw a dramatic increase in Genmab’s
    stock price and market capitalization in 2006. Our
    stock price increased 181% from DKK 135 (approx.
    USD 24) on December 31, 2005 to DKK 380 (approx.
    USD 67) a year later. Our market capitalization also
    significantly increased by 235% from DKK 4.5 billion
    (approx. USD 795 million) to DKK 15.07 billion
    (approx. USD 2.66 billion) in 2006.

    Building for a Commercial Future
    Genmab started three new pivotal Phase III clinical
    studies in 2006: HuMax-CD20 for refractory chronic
    lymphocytic leukemia (CLL) and rituximab refractory
    follicular non-Hodgkin’s lymphoma (NHL) and
    HuMax-EGFr™ (zalutumumab) for refractory head
    and neck cancer. We also initiated front line
    combination studies of HuMax-EGFr for head and
    neck cancer and HuMax-CD20 for CLL. Starting front
    line studies with these potential cancer products is a
    new step for Genmab, one that may eventually open up
    more opportunities for our products in the marketplace.
    These pivotal and front line studies have the potential
    to serve as stepping stones on Genmab’s pathway
    towards a commercial future.
    We have also continued to make progress in our
    ongoing development programs. We reported positive
    results in three HuMax-CD20 studies: Phase I/II
    rheumatoid arthritis (RA); interim Phase II RA; and
    Phase I/II CLL duration of response data. In the
    HuMax-CD4 program with Merck Serono S.A. we
    announced positive early results in both the Phase III
    cutaneous T-cell lymphoma (CTCL) and Phase II noncutaneous
    T-cell lymphoma studies. We received Fast
    Track status from the US FDA for HuMax-EGFr in
    refractory head and neck cancer and presented preclinical
    data showing that HuMax-EGFr appears to be
    more effective against variations of the EGF receptor
    than other EGFr directed treatments. We also
    announced that in pre-clinical studies HuMax-CD38™
    was the first antibody shown to inhibit the enzymatic
    activity of the CD38 molecule.
    Genmab remains committed to maintaining a broad and
    diversified product pipeline. With a product portfolio
    consisting of 38 potential products including 18 preclinical
    programs and an additional 14 targets under
    exploration, we are building for the possibility of
    sustained growth in the future.

    UniBody - The Next Step in Antibody Development
    Genmab’s scientific team unveiled the innovative new
    UniBody technology that has the potential to increase
    the market for antibody therapeutics. UniBodies are
    stable, smaller antibody formats which, based on preclinical
    data, are expected to last longer in the human
    body than current small antibody formats, lengthening
    the window of opportunity for a treatment to take
    effect. We believe this technology has the potential to
    expand the market for targeted therapeutics especially
    in disease areas like cancer and inflammation where the
    small size and special binding characteristics of
    UniBodies may make them more effective than
    traditional antibody formats. Genmab is beginning to
    develop antibody products using the UniBody
    technology and may consider out-licensing the
    technology to other companies.

    www.genmab.com/upload/ifrs_report_200...
  6. [verwijderd] 16 februari 2007 11:47
    De daling van de laatste dagen blijkt tgv verkoop van de 2.5 M aandelen door Medarex. Een derde hiervan schijnt (volgens Bloomberg) bij GS te zijn gekomen.

    Aangezien de vorige CEO Drakeman weg is, is er verder weinig reden om die aandelen aantehouden. Opvoeren kaspositie voor MEDX is ook aantrekkelijk.

    De reden van de Genmab koersdaling is dus plausibel. Bijgevolg vandaag weer + 10 DK..

    Wellicht koers nu weer verder Up...
    JMHO
  7. [verwijderd] 20 februari 2007 12:37
    More Biotech Cos Seen Listing On Copenhagen Bourse In 07Last update: 2/19/2007 7:34:53 AMSTOCKHOLM

    (Dow Jones)--The success of Danish biotechnology companies is expected to encourage more companies in the sector to list on the Copenhagen Stock Exchange in 2007, market watchers say. Jens Peter Toft, global head of corporate finance at Danske Bank, says he expects that 2007 will see healthy initial public offering activity in Denmark dominated in number of transactions by biotechnology companies. "The window for IPOs is definitely there right now. There is a good balance between what sellers and buyers want respectively," he says. Companies mentioned as potential IPO candidates include 7TM Pharma, Natimmune, Egalet, Gastrotech Pharma, Symphogen, Santaris, M2 Medical and Millimed. Florian Schoenharting, co-founder and partner of venture capital firm Nordic Biotech, says that of these, 7TM Pharma stands out as the flagship company. "It has first-class investors involved, they are in phase II with their drug for obesity, which is a big indication, and they have done some international deals," he said. Schoenharting added that Gastrotech and Egalet are also interesting as both companies have good, late-stage products and Egalet also has the advantage of being supported by top venture capital firm Index Ventures. Egalet has two products in late-stage research for the treatment of high blood pressure and pain management and Gastrotech has two drugs in phase II research for catabolic disorders and irritable bowel syndrome. The positive sentiment for biotechnology investments in Denmark has been triggered by a number of companies entering lucrative contracts with international pharmaceutical firms. In December, Genmab A/S (GEN.KO) signed a potential $2.1 billion partnership deal with GlaxoSmithKline PLC (GSK) for its blood cancer drug HuMax-CD20, and shortly after, peer ALK-Abello A/S (ALK-B.KO) entered a contract with Schering-Plough Corp. (SGP), worth up to $255 million for the allergy vaccine Grazax. After nearly five years of no listing activity at all, the Copenhagen stock exchange in the past year and a half has seen three initial public offerings in the biotechnology sector. TopoTarget A/S (TOPO.KO) entered the exchange in June 2005 by raising DKK225 million, followed by Curalogic and LifeCycle Pharma A/S (LCP.KO) in 2006, raising DKK201.6 million and DKK556.6 million, respectively. In total, the biotechnology companies on the Copenhagen Stock Exchange now have a market capitalization of as much as DKK38.8 billion ($6.8 billion.) -By Malin Rising, Dow Jones Newswires; +45 33 111 524; malin.rising@dowjones.com (END) Dow Jones NewswiresFebruary 19, 2007 07:34 ET (12:34 GMT)
  8. [verwijderd] 20 februari 2007 13:07
    Medarex Announces Sale of Shares in Genmab A/S
    Tuesday February 20, 7:00 am ET

    PRINCETON, N.J., Feb. 20 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX - News) announced today that it has sold approximately 2.5 million shares of Genmab A/S which stock is traded on the Copenhagen Stock Exchange. The trade is expected to settle on February 21, 2007. Medarex expects to receive approximately $150 million (USD) in net proceeds from the sale. The sale of Genmab shares is expected to reduce Medarex's equity ownership in Genmab to approximately 11 percent.

    Dirk.

    --------------------------------------------------------------------------------
    Source: Medarex, Inc.
  12. pim f 26 februari 2007 21:27
    quote:

    Edjes1 schreef:

    En weer dalen.
    Het lijkt erop dat er een kop-schouder patroon ontwikkelt? Dan kunnen we terug naar 250....
    Met de daling van vandaag (naar 321) ben ik ook wel overtuigd van een terugkeer richting 250. Ik zit helemaal standby om er vol in te kletsen als die 250 benaderd wordt.
  17. [verwijderd] 27 februari 2007 14:13
    GENMAB TO PRESENT AT NINTH ANNUAL BEAR STEARNS LONDON HEALTHCARE CONFERENCE
    Copenhagen, Denmark; February 22, 2007 – Genmab A/S (CSE: GEN) announced today its CEO, Lisa N. Drakeman, Ph.D., will present at the Ninth Annual Bear Stearns London Healthcare Conference on February 27 at 12 Noon local time. The conference is being held at the Four Seasons Hotel, Park Lane in London, United Kingdom. Approximately 150 healthcare investors from Europe and the United States are expected to attend the conference.
    Dr. Drakeman’s presentation will be accessible via live and archived webcast at Genmab's website www.genmab.com.
    www.genmab.com/upload/02_bear_stearns...

    cc.talkpoint.com/BEAR002/022707b_cy/l...
    Bijlage:
  19. [verwijderd] 19 maart 2007 09:46
    Hierbij het laatste nieuws over Genmab. Genmab is present op de grootste wereld conferency van hun beroepsgroep (200 bedrijven) en zal daar weer nieuwe producten presenteren, wil je dit life volgen, dat kan via hun website: www.genmab.com op 21 maart om 10.15.

    Copenhagen, Denmark; March 19, 2007 - Genmab A/S (CSE: GEN) announced today its CEO, Lisa N. Drakeman, Ph.D., will present at the Lehman Brothers Tenth Annual Global Healthcare Conference in Miami on March 21 at 10:15AM local time. The conference will feature presentations from nearly 200 companies in the biotechnology and pharmaceutical industries.

    Dr. Drakeman's presentation will be accessible via live and archived webcast at Genmab's website www.genmab.com.

    Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. At present, Genmab has multiple partnerships to gain access to disease targets and develop novel human antibodies including agreements with Roche and Amgen. A broad alliance provides Genmab with access to Medarex, Inc.'s array of proprietary technologies, including the UltiMAb(R) platform for the rapid creation and development of human antibodies to virtually any disease target. In addition, Genmab has developed UniBody(TM), a new proprietary technology that creates a stable, smaller antibody format. Genmab has operations in Europe and the US.

    Dit zijn de produkten waar Genmab al het alleenrecht voor heeft, dus dat belooft nog wat:

    Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-EGFr(TM);
    HuMax-Inflam(TM); HuMax-CD20(TM); HuMax-TAC(TM); HuMax-HepC(TM), HuMax-CD38(TM);
    HuMax-ZP3(TM); and UniBody(TM) are all trademarks of Genmab A/S.

    groetjes peter
145 Posts
Pagina: «« 1 2 3 4 5 6 ... 8 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
HEIJMANS KON 29,800 +2,20 +7,97%
AZERION 1,300 +0,05 +4,00%
AMG Critical Materials N.V. 15,200 +0,44 +2,98%
ArcelorMittal 23,990 +0,48 +2,04%
SIGNIFY NV 22,100 +0,38 +1,75%
ASR Nederland 44,940 +0,63 +1,42%
Aperam 28,220 +0,38 +1,36%
TKH 33,620 +0,42 +1,27%
Accsys 0,585 +0,01 +1,04%
Aegon 6,112 +0,06 +0,99%
PostNL 1,053 +0,01 +0,96%
ING 14,978 +0,14 +0,96%
SHELL PLC 31,055 +0,24 +0,78%
NN Group 45,300 +0,35 +0,78%
Kendrion 10,920 +0,08 +0,74%
RANDSTAD NV 41,600 +0,30 +0,73%
ACOMO 17,260 +0,12 +0,70%
RENEWI 7,430 +0,05 +0,68%
ASCX 1.209,03 +6,48 +0,54%
ALLFUNDS GROUP 5,345 +0,02 +0,47%
Flow Traders 21,200 +0,08 +0,38%
Air France-KLM 7,700 +0,02 +0,23%
Eurocommercial Properties 23,300 +0,05 +0,22%
BAM 4,170 +0,01 +0,19%
Sif Holding 12,240 +0,02 +0,16%
Wereldhave 14,100 +0,02 +0,14%
Fugro 16,130 +0,02 +0,12%
NSI 19,660 +0,02 +0,10%
DSM FIRMENICH AG 102,550 +0,05 +0,05%
UNILEVER PLC 54,400 +0,02 +0,04%
Brunel 8,590 0,00 0,00%
JDE PEET'S 18,500 0,00 0,00%
SBM Offshore 17,570 0,00 0,00%
TomTom 5,420 0,00 0,00%

Dalers

instrument koers absoluut verschil relatief verschil
EBUSCO (RIGHT) 0,160 -0,22 -57,89%
EBUSCO HOLDING 1,266 -0,12 -8,86%
ASML 635,000 -36,60 -5,45%
Wolters Kluwer 151,650 -7,25 -4,56%
ASMI 507,600 -21,60 -4,08%
RELX 42,300 -1,48 -3,38%
Galapagos 25,540 -0,84 -3,18%
ADYEN NV 1.237,000 -39,80 -3,12%
Arcadis 62,950 -1,85 -2,85%
Pharming 0,715 -0,02 -2,79%
BESI 114,350 -2,90 -2,47%
Avantium 2,190 -0,06 -2,45%
B&S Group SA 4,300 -0,10 -2,27%
Corbion 21,840 -0,46 -2,06%
NX FILTRATION 4,540 -0,09 -2,05%
IMCD 142,150 -2,90 -2,00%
ForFarmers 3,350 -0,06 -1,90%
UMG 23,100 -0,44 -1,87%
INPOST 17,300 -0,27 -1,54%
Basic-Fit 22,820 -0,34 -1,47%
AEX 862,50 -11,98 -1,37%
THEON INTERNAT 8,980 -0,12 -1,32%
EXOR NV 93,600 -1,25 -1,32%
CM.COM 6,200 -0,08 -1,27%
Fagron 18,520 -0,20 -1,07%
Sligro 11,120 -0,12 -1,07%
JUST EAT TAKEAWAY 14,105 -0,14 -0,95%
PROSUS 37,750 -0,34 -0,88%
Heineken 71,340 -0,52 -0,72%
Ahold Delhaize 32,130 -0,22 -0,68%
FASTNED 22,050 -0,15 -0,68%
Van Lanschot Kempen NV 44,500 -0,30 -0,67%
Vastned 24,350 -0,15 -0,61%
Alfen N.V. 12,400 -0,07 -0,56%
AMX 870,21 -4,77 -0,55%
ABN AMRO BANK N.V. 14,790 -0,08 -0,54%
KPN 3,524 -0,02 -0,51%
WDP 20,620 -0,08 -0,39%
Nedap N.V. 53,400 -0,20 -0,37%
Akzo Nobel 55,680 -0,20 -0,36%
AALBERTS NV 35,220 -0,12 -0,34%
OCI 11,245 -0,03 -0,27%
Vopak 43,640 -0,10 -0,23%
Philips Koninklijke 24,560 -0,05 -0,20%
CTP 14,760 -0,02 -0,14%
vlag naam koers verschil relatief verschil
AEX 862,50 -11,98 -1,37%
AEX GR 3.382,99 -47,01 -1,37%
Germany40^ 19.239,20 -24,50 -0,13%
FTSE 100 8.063,61 -7,58 -0,09%
EURO50 4.796,06 0,00 0,00%
US30^ 43.483,80 0,00 0,00%
Nasd100^ 20.407,80 0,00 0,00%
US500^ 5.874,88 0,00 0,00%
Japan225^ 38.006,50 0,00 0,00%
VD-NEW 16,30 +0,17 +1,06%
#/^ Index indications calculated real time, zie disclaimer